Market revenue in 2023 | USD 257.6 million |
Market revenue in 2030 | USD 1,041.7 million |
Growth rate | 22.1% (CAGR from 2023 to 2030) |
Largest segment | Commercial |
Fastest growing segment | Commercial |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Clinical, Preclinical, Commercial |
Key market players worldwide | Roche, Wuxi AppTec Co Ltd, Pfizer Inc, Astellas Pharma Inc, Lifespan, Genscript Biotech Corp Class H, Biomarin Pharmaceutical Inc, Oxford Biomedical Research, Sarepta Therapeutics Inc, YposKesi |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to adeno associated virus vector manufacturing market will help companies and investors design strategic landscapes.
Commercial was the largest segment with a revenue share of 56.17% in 2023. Horizon Databook has segmented the Europe adeno associated virus vector manufacturing market based on clinical, preclinical, commercial covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe adeno associated virus vector manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into Europe adeno associated virus vector manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account